Biodexa announces pricing of $5.2 million underwritten public offering

Biodexa pharmaceuticals plc (“biodexa” or the “company”) cardiff, united kingdom, dec. 19, 2023 (globe newswire) -- biodexa pharmaceuticals plc, (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the pricing of an underwritten public offering of units. ladenburg thalmann & co. inc. is acting as sole book-running manager in connection with the offering.
BDRX Ratings Summary
BDRX Quant Ranking